Moderately activates human somatostatin receptors (SSTR) with a preferential activation of SSTR1 and SSTR4. In vivo, does not cause behavioral changes in mice within a few minutes of intracranial injection, but causes a progressive loss of movement thereafter. Four to five hours after injection, mice recover, even with the highest dose tested. Shows antinociception and antihyperalgesia activities in two mouse models of acute pain, most probably by acting outside the central nervous system. Expressed by the venom duct. The cysteine framework is C-C. This peptide is an evolutionarily optimized stable analog of somatostatin. In addition, it adopts nearly identical conformations as in the somatostatin drug analog Octreotide. As this drug, it contains a D-Trp at the same position, whose synthesis is a common strategy used for enhancing the metabolic stability of compounds in drug design. Consomatins evolved by gene duplication of a 'Somatostatin and related peptides (SSRP)' gene expressed in the snail neuroendocrine system. Does not activate any of the other 313 GPCRs tested. Shows little or no activating activity at the SSTR2, SSTR3 and SSTR5. Belongs to the conotoxin C superfamily. Consomatin family.